Data Availability No datasets were generated or analysed during the current study
RV-8451, differentiated oral, muscle-preserving GLP-1 candidate for obesity Recent Highlights: In February 2026, Rivus stated it was entering a pivotal year, advancing HU6 in the AMPLIFY Phase 2 MASH trial while preparing the first clinical trial for RV-8451, its muscle-preserving oral GLP-1 candidate, designed to address the muscle-loss criticism leveled at existing GLP-1 therapies
The pathogenesis of diabetes involves a defective amplification of the late phase insulin response to glucose by GIPregardless of aetiology and phenotype
Working with a sports dietitian and sports physician is highly advised to ensure all nutrient needs are met
NICE guidance (NG28) recommends GLP-1 receptor agonists for adults with type 2 diabetes in specific clinical circumstances
Patients should verify the legitimacy of online pharmacies before purchasing retatrutide to avoid counterfeit products